NRAS G12/G13

CI-VAR-00001587Explore in graph →p.Gly13AspNM_002524.5:c.38G>AClinVar 13901 CIViC 596 rs121434596

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia1
NRAS G12/G13	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID1516 Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate o… (full text at CIViC) PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13901	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Juvenile myelomonocytic leukemia; Noonan syndrome 6; Autoimmune lymphoproliferative syndrome type 4; Acute megakaryoblastic leukemia in down syndrome; Neoplasm; RASopathy; Acute myeloid leukemia with NPM1 somatic mutations; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; Embryonal rhabdomyosarcoma; RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER 1, SOMATIC; NRAS-related disorder; Colorectal cancer; Melanoma; Acute myeloid leukemia